吉西他滨联合奥沙利铂治疗晚期非小细胞肺癌46例临床分析

目的：观察吉西他滨联合奥沙利铂治疗晚期非小细胞肺癌的临床疗效及不良反应。方法：46例Ⅲb期，IV期，经病理学或者细胞学确诊为非小细胞肺癌患者，采用吉西他滨与奥沙利铂联合化疗方案。吉西他滨1000mgm2，静脉滴注，第1天及第8天，奥沙利铂130re#m2静脉滴注，第1天，21天为1周期，连用2周期后评价疗效及不良反应。结果：全组有效率45．65％，其中CR3例，PR18例，SD14例，PD11例。主要不良反应为骨髓抑制和神经系统毒性。结论：吉西他滨联合奥沙利铂治疗晚期非小细胞癌疗效较好，不良反应轻，容易耐受。

Gemcitabine and Oxaliplatin Combination Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

Objective：To evaluate the efficacy and toxicity of gemcitabine （GEM） and oxaliplatin （LOHP） combination chemotherapy in patients with advanced non-small-cell lung cancer. Methods：46 patients with advanced NSCLC diagnosed pathologically were treated with the combination chemotherapy （GEM 1000 mg/m2 on day 1.8 and LOHP 130 mg/m2 on day 1）. Each patient was given 2 cycles at an interval of 3 weeks, and the efficacy and toxicity were then evaluated.Results：The overall response rate was 45.65%. The main toxicity presented as myelosuppression and neurotoxieity.Conclusion ： The combination chemotherapy of gemeitabine and oxaliplatin is an effective chemotherapy with acceptable toxieities for advanced NSCLC.